Argenx has agreed to acquire Unnatural Products, a biotechnology firm working on a macrocyclic peptide platform. One report says the deal would give Argenx control of the technology in a transaction that includes $550 million paid upfront, with the stated focus on developing oral, durable medicines for serious immune-mediated diseases.

Other coverage frames the acquisition as a much larger total consideration, reporting a $1.15 billion figure for the transaction. Together, the outlets indicate the same core change—Argenx taking over Unnatural Products’ peptide technology—while differing on how the overall price is presented and whether it is described as an upfront payment or as the total deal value. Neither source summary provides additional detail on timing, regulatory steps, or future product candidates beyond the intended therapeutic direction.